CL2016002683A1 - Proteínas agonistas de los receptores de trail de cadena simple - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple

Info

Publication number
CL2016002683A1
CL2016002683A1 CL2016002683A CL2016002683A CL2016002683A1 CL 2016002683 A1 CL2016002683 A1 CL 2016002683A1 CL 2016002683 A CL2016002683 A CL 2016002683A CL 2016002683 A CL2016002683 A CL 2016002683A CL 2016002683 A1 CL2016002683 A1 CL 2016002683A1
Authority
CL
Chile
Prior art keywords
receptor agonist
agonist proteins
single chain
trail receptor
trail
Prior art date
Application number
CL2016002683A
Other languages
English (en)
Spanish (es)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Fritz G Buchanan
Darren C Phillips
Susan E Lappe
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of CL2016002683A1 publication Critical patent/CL2016002683A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
CL2016002683A 2014-04-23 2016-10-21 Proteínas agonistas de los receptores de trail de cadena simple CL2016002683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
CL2016002683A1 true CL2016002683A1 (es) 2017-07-07

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002683A CL2016002683A1 (es) 2014-04-23 2016-10-21 Proteínas agonistas de los receptores de trail de cadena simple

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3366699A1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN106459221B (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA2946402C (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA39770A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG11201608767XA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
JP6873119B2 (ja) * 2015-10-23 2021-05-19 アポジェニックス アーゲー 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
EP3365363A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain gitr-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
CN108884142A (zh) * 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 用于癌症治疗的工程化trail
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2018313253B2 (en) 2017-08-11 2024-09-26 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
TW202002952A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
CN115836084A (zh) 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
AU2022281108A1 (en) 2021-05-28 2023-12-14 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
ATE445644T1 (de) * 2005-04-15 2009-10-15 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
ES2657801T3 (es) 2007-07-10 2018-03-06 Apogenix Ag Proteínas de fusión de colectina de la superfamilia de TNF
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
WO2010033315A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
WO2010042890A2 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
BRPI1006998A2 (pt) * 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
JP2013514795A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
CA2796010C (en) * 2010-04-13 2020-05-12 Medimmune, Llc Trail r2-specific multimeric scaffolds
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants

Also Published As

Publication number Publication date
PH12016502079B1 (en) 2016-12-19
AU2015249649A1 (en) 2016-11-10
IL272612A (en) 2020-03-31
IL248244A0 (en) 2016-11-30
KR20170012257A (ko) 2017-02-02
ECSP16089579A (es) 2018-05-31
SG10202111785VA (en) 2021-12-30
UA118286C2 (uk) 2018-12-26
CN106459221B (zh) 2020-09-01
SG11201608767XA (en) 2016-11-29
MX2016013858A (es) 2017-08-02
NZ725476A (en) 2023-09-29
EP3366699A1 (en) 2018-08-29
MY181986A (en) 2021-01-18
SI3134430T1 (en) 2018-05-31
TW201620928A (zh) 2016-06-16
US20210040178A1 (en) 2021-02-11
AR100168A1 (es) 2016-09-14
DK3134430T3 (en) 2018-05-22
US20240174731A1 (en) 2024-05-30
SMT201800286T1 (it) 2018-07-17
IL248244B (en) 2020-03-31
TW202024123A (zh) 2020-07-01
JP6714751B2 (ja) 2020-06-24
BR112016024515B1 (pt) 2020-03-31
NO2776305T3 (enExample) 2018-01-27
MA45069A (fr) 2019-04-03
MX2019013587A (es) 2020-01-13
PH12016502079A1 (en) 2016-12-19
TWI747178B (zh) 2021-11-21
SG10201806465TA (en) 2018-08-30
KR20190135546A (ko) 2019-12-06
US20180222962A1 (en) 2018-08-09
KR102079919B1 (ko) 2020-02-24
JP2019162114A (ja) 2019-09-26
EP3134430B1 (en) 2018-03-21
US20250145688A1 (en) 2025-05-08
WO2015164588A1 (en) 2015-10-29
LT3134430T (lt) 2018-05-10
CA2946402A1 (en) 2015-10-29
AU2018271369A1 (en) 2018-12-20
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
RU2016145608A (ru) 2018-05-28
CA2946402C (en) 2023-02-28
MA39770A (fr) 2015-10-29
JP6523331B2 (ja) 2019-05-29
AU2015249649B2 (en) 2018-10-04
ES2672368T3 (es) 2018-06-14
CR20160516A (es) 2017-05-10
RS57153B1 (sr) 2018-07-31
TWI683825B (zh) 2020-02-01
US9908927B2 (en) 2018-03-06
EP3134430A1 (en) 2017-03-01
UY36095A (es) 2015-10-30
DOP2016000284A (es) 2017-02-15
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
CY1120281T1 (el) 2019-07-10
RU2016145608A3 (enExample) 2018-12-26
TR201806912T4 (tr) 2018-06-21
BR112016024515A2 (pt) 2017-10-10
AU2020202247A1 (en) 2020-04-23
PH12020500377A1 (en) 2022-11-14
US20150337027A1 (en) 2015-11-26
JP2017513503A (ja) 2017-06-01
RU2699285C2 (ru) 2019-09-04
PE20170299A1 (es) 2017-05-06
PT3134430T (pt) 2018-04-20
HRP20180950T1 (hr) 2018-08-10
PL3134430T3 (pl) 2018-08-31
HUE038914T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
AR100168A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX379136B (es) Proteinas agonistas receptoras cd40 de cadena sencilla.
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
MX2022009463A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
PL3114145T3 (pl) Przeciwciała przeciw ludzkiemu białku pomocniczemu receptora interleukiny-1 (il1rap) i ich zastosowania
BR112016010822A2 (pt) anticorpos específicos para fcrn
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112017023131A2 (pt) anticorpos anti- fcrn
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
EA201790356A1 (ru) Метил- и трифторметилзамещенные пирролопиридиновые модуляторы rorc2 и способы их применения